Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dublin, Ireland - April 18, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on rare diseases, announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has validated the marketing authorization application (MAA) for lanadelumab (SHP643). The validation of the MAA confirms that the lanadelumab MAA submission is complete and that the formal review process will begin. Lanadelumab is an investigational treatment being evaluated for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE). Lanadelumab was also designated orphan drug status by Swissmedic.
No, this is al the major ie 1%+ shareholders (like Vanguard Group, Blackrock Group, etc) declaring their daily dealings under Rule 8.3. They need to declare such daily dealings/interests in both the offeror and offeree (by the day after the transaction took place)...some are purchases and some are sales. ATB, Scfc
Every day i keep reading 8.3 takeda i assumed this was announcements that they were buying more shares and disclosing the information.
Bewarethebrokers, under the U.K. Takeover rules (Rule 8) anyone with over 1% of an interest must declare this interest within 10 days of the “starting period” and thereafter declare any further dealings so this cannot be the case during said offer period. ATB, Scfc
I think takeda are still buying up shares so saying nothing until the last minute makes more sense because the share price will be kept low. Hopefully some of the other big pharma companies will enter the bidding. I think we all deserve it for the pain shire has put us all through!
if oncology was the main attraction for takeda then they would have come out by now saying deal is off. So my guess is they are working on an offer still and will say something on the last day of the deadline.
if oncology was the main attraction for takeda then they would have come out by now saying deal is off. So my guess is they are working on an offer still and will say something on the last day of the deadline.
Well, little real news again and Takeda seemingly wanting to take all the time that the Takeover rules allow them. Was at least expecting some more “sources close to...” articles saying something random at the very least. So rather than speculating on whether there’ll be a bid, or the value on this BB, how about speculating on the date of their Stock Exchange announcement. I’m going for Monday 23rd April! Scfc
You're all good mate, no matter what we say here, shire price will move the way market wants it to move :-)
Where-is, My last message was tongue in cheek but may have come across as a serious response. It wasn't. ;-)
We're not talking it down. We're merely talking about why it has fallen on a daily basis. Don't shoot the messenger.
Morning all, shp up a touch like yesterday morning. Will it turn red like yesterday afternoon? Well lets talk it down like we do every day of the week shall we :-)
UT close was £35.59. ATB, Scfc
Good point scfc. And I also agree that this is all SPECULATION and none of us know any facts. Just our opinion.
We need the market to have that blind faith again so I can get out with a decent profit :-)
Fair analysis imo, redtom, and in addition it should also be noted that Takeda’s SP rose by over 2% earlier today...it has always fallen when the likelihood of a deal (or perhaps should say I speculation of the deal) has increased. But of course none of us know anything for sure as yet...
This opened at 3732p and is now around 3536p. That's one hell of a change in sentiment given there has been no new news since opening. People know something but not everyone.
Looks like the markets are coming to the same conclusion that it is now highly unlikely that Takeda will make a formal bid. The sale of Oncology this morning, the current �:$ fx rate and the respective difference in SP has scuppered this deal. All in my opinion only but I just can't see any scenario where this works. If I was a Takeda shareholder, I would be bailing or screaming at the BoD not to do the deal.
They assumed this was still a growth stock. But poor management and over paying for acquisitions has made this a slow growth if, if any growth. Hence turnover forecast fell from $20bn to $18bn for 2020. The markets had blind faith in the management but are now starting to realise that FO and the BoD are not up to the job.
What was the justification in shp trading at over �50 last year? What did the market assume then i wonder?
Quite possibly, but markets don’t just look at one thing in isolation and assume everything else is valued correctly so the maths then work as a result. If only it were that simple. ATB, Scfc
Because a Takeda bid is less likely?
No wait, make that a drop of about half a percent
This cash from disposal is about 5% of the current MCap right? Why are we only seeing a less than 1% gain in sp?
because of various factors including lack of preparedness, I do not believe the takeover will happen this time round. we will find out soon though. I have sold my holdings as i would prefer to use funds elsewhere for now but I still maintain a 'hold' on SHP as i believe a takeover will occur. It is just a matter of when not if. GLA